These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 3123510)

  • 1. Serum bioactive and immunoreactive follicle-stimulating hormone in prostatic cancer patients during gonadotropin-releasing hormone agonist treatment and after orchidectomy.
    Huhtaniemi IT; Dahl KD; Rannikko S; Hsueh AJ
    J Clin Endocrinol Metab; 1988 Feb; 66(2):308-13. PubMed ID: 3123510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The ratios of serum bioactive/immunoreactive luteinizing hormone and follicle-stimulating hormone in various clinical conditions with increased and decreased gonadotropin secretion: reevaluation by a highly sensitive immunometric assay.
    Jaakkola T; Ding YQ; Kellokumpu-Lehtinen P; Valavaara R; Martikainen H; Tapanainen J; Rönnberg L; Huhtaniemi I
    J Clin Endocrinol Metab; 1990 Jun; 70(6):1496-505. PubMed ID: 2140831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response of circulating gonadotropin levels to GnRH agonist treatment in prostatic cancer.
    Huhtaniemi I; Venho P; Jacobi G; Rannikko S
    J Androl; 1991; 12(1):46-53. PubMed ID: 1901309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pituitary-testicular function of prostatic cancer patients during treatment with a gonadotropin-releasing hormone agonist analog. I. Circulating hormone levels.
    Huhtaniemi I; Nikula H; Rannikko S
    J Androl; 1987; 8(6):355-62. PubMed ID: 3123445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of prostatic cancer with a gonadotropin-releasing hormone agonist analog: acute and long term effects on endocrine functions of testis tissue.
    Huhtaniemi I; Nikula H; Rannikko S
    J Clin Endocrinol Metab; 1985 Oct; 61(4):698-704. PubMed ID: 2993345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of oestrogen treatment on serum gonadotrophin bioactivity, immunoreactivity and isohormone distribution, and on immunoreactive inhibin levels, in prostatic cancer patients.
    Matikainen T; Haavisto AM; Permi J; de Kretser D; Huhtaniemi I
    Clin Endocrinol (Oxf); 1994 Jun; 40(6):743-50. PubMed ID: 8033364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differing responses of plasma bioactive and immunoreactive follicle-stimulating hormone and luteinizing hormone to gonadotropin-releasing hormone antagonist and agonist treatments in postmenopausal women.
    Matikainen T; Ding YQ; Vergara M; Huhtaniemi I; Couzinet B; Schaison G
    J Clin Endocrinol Metab; 1992 Sep; 75(3):820-5. PubMed ID: 1517372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. More basic isoforms of serum gonadotropins during gonadotropin-releasing hormone agonist therapy in pubertal children.
    Wide L; Albertsson-Wikland K; Phillips DJ
    J Clin Endocrinol Metab; 1996 Jan; 81(1):216-21. PubMed ID: 8550754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maintenance of the ratio of bioactive to immunoreactive follicle-stimulating hormone in normal men during chronic luteinizing hormone-releasing hormone agonist administration.
    Pavlou SN; Dahl KD; Wakefield G; Rivier J; Vale W; Hsueh AJ; Lindner J
    J Clin Endocrinol Metab; 1988 May; 66(5):1005-9. PubMed ID: 2834409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The changing ratio of serum bioactive to immunoreactive follicle-stimulating hormone in normal men following treatment with a potent gonadotropin releasing hormone antagonist.
    Dahl KD; Pavlou SN; Kovacs WJ; Hsueh AJ
    J Clin Endocrinol Metab; 1986 Sep; 63(3):792-4. PubMed ID: 3090097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hormonal effects of gonadotropin-releasing hormone (GnRH) agonist in the human male. III. Effects of long term combined treatment with GnRH agonist and androgen.
    Bhasin S; Heber D; Steiner BS; Handelsman DJ; Swerdloff RS
    J Clin Endocrinol Metab; 1985 May; 60(5):998-1003. PubMed ID: 3920237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum bioactive follicle-stimulating hormone levels in girls with precocious sexual development.
    Wang C; Zhong CQ; Leung A; Low LC
    J Clin Endocrinol Metab; 1990 Mar; 70(3):615-9. PubMed ID: 2106526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Granulosa cell aromatase bioassay for follicle-stimulating hormone: validation and application of the method.
    Jia XC; Hsueh AJ
    Endocrinology; 1986 Oct; 119(4):1570-7. PubMed ID: 2428600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hormonal effects of gonadotropin-releasing hormone (GnRH) agonist in men: effects of long term treatment with GnRH agonist infusion and androgen.
    Bhasin S; Yuan QX; Steiner BS; Swerdloff RS
    J Clin Endocrinol Metab; 1987 Sep; 65(3):568-74. PubMed ID: 3114307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum bioactive and immunoreactive follicle-stimulating hormone levels and the response to clomiphene in healthy young and elderly men.
    Tenover JS; Dahl KD; Hsueh AJ; Lim P; Matsumoto AM; Bremner WJ
    J Clin Endocrinol Metab; 1987 Jun; 64(6):1103-8. PubMed ID: 3106393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gonadotropin-releasing hormone regulates follicle-stimulating hormone beta-subunit gene expression in the male rat.
    Rodin DA; Lalloz MR; Clayton RN
    Endocrinology; 1989 Sep; 125(3):1282-9. PubMed ID: 2503366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum bioactive and immunoreactive follicle stimulating hormone during chronic treatment with gonadotropin releasing hormone agonist in elderly men.
    Matzkin H; Braf Z; Dekel N
    Horm Metab Res; 1991 Feb; 23(2):76-80. PubMed ID: 1710593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recovery of hormone secretion after chronic gonadotropin-releasing hormone agonist administration in women with polycystic ovarian disease.
    de Ziegler D; Steingold K; Cedars M; Lu JK; Meldrum DR; Judd HL; Chang RJ
    J Clin Endocrinol Metab; 1989 Jun; 68(6):1111-7. PubMed ID: 2524501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum luteinizing hormone (LH) biological activity in castrated patients with cancer of the prostate receiving a pure antiandrogen and in estrogen-pretreated patients treated with an LH-releasing hormone agonist and antiandrogen.
    St Arnaud R; Lachance R; Dupont A; Labrie F
    J Clin Endocrinol Metab; 1986 Aug; 63(2):297-302. PubMed ID: 3522618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gonadotroph adenomas in men produce biologically active follicle-stimulating hormone.
    Galway AB; Hsueh AJ; Daneshdoost L; Zhou MH; Pavlou SN; Snyder PJ
    J Clin Endocrinol Metab; 1990 Oct; 71(4):907-12. PubMed ID: 2119391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.